Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention

被引:21
作者
Danzi, GB [1 ]
Capuano, C [1 ]
Sesana, M [1 ]
Baglini, R [1 ]
机构
[1] Poliambulanza Hosp, Catheterisat Lab, Brescia, Italy
关键词
angioplasty; platelet inhibition; stents; tirofiban;
D O I
10.1185/030079902125001380
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In the TARGET study, sub-optimal platelet inhibition with tirofiban was held responsible for the higher incidence of periprocedural CK-MB release compared to abciximab. Since then, a new, higher bolus dose of tirofiban has been proposed to increase blood concentrations very soon after the start of treatment. Objective: The aim of this study was to explore the bleeding risk and clinical outcome at 30 days in a series of patients undergoing percutaneous coronary intervention (PCI) with the new dosing regimen of tirofiban (25mug/kg bolus followed by a 0.15mug kg(-1) min(-1) infusion for 18h). Methods: A total of 133 consecutive patients underwent a PCI and received a high bolus dose of tirofiban. Platelet function inhibition was measured using the Ultegra(TM) RPFA (Accumetrics) 10 min and 8 and 24 h after the start of therapy in the first 38 cases. Results: The procedural success rate was 98.5%. The mean level of platelet inhibition 10 min after the start of therapy was 94.7 +/- 5.9%. No major bleedings, no need for red blood cell transfusion and no episodes of severe thrombocytopoenia were recorded. Groin haematoma was observed in seven patients (5.3%). The cumulative incidence of 30-day major adverse cardiovascular events was 4.6% (five myocardial infarctions and one repeat PTCA for sub-acute stent thrombosis). Conclusions: The use of a high bolus dose of tirofiban in patients undergoing PCI seems to be safe and not associated with an increased risk of major bleeding. This high bolus dose may help to further reduce the rate of periprocedural adverse events.
引用
收藏
页码:28 / 33
页数:6
相关论文
共 21 条
  • [1] Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention
    Brown, DL
    Fann, CSJ
    Chang, CJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (05) : 537 - 541
  • [2] Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon, CP
    Weintraub, WS
    Demopoulos, LA
    Vicari, R
    Frey, MJ
    Lakkis, N
    Neumann, FJ
    Robertson, DH
    DeLucca, PT
    DiBattiste, PM
    Gibson, CM
    Braunwald, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) : 1879 - 1887
  • [3] Cook JJ, 1999, CARDIOVASC DRUG REV, V17, P199
  • [4] Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices
    Dangas, G
    Mehran, R
    Kokolis, S
    Feldman, D
    Satler, LF
    Pichard, AD
    Kent, KM
    Lansky, AJ
    Stone, GW
    Leon, MB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (03) : 638 - 641
  • [5] Which variable of stenosis severity best describes the significance of an isolated left anterior descending coronary artery lesion? Correlation between quantitative coronary angiography, intracoronary Doppler measurements and high dose dipyridamole echocardiography
    Danzi, GB
    Pirelli, S
    Muri, L
    Testa, R
    Ciliberto, GR
    Massa, D
    Lotto, AA
    Campolo, L
    Parodi, O
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (03) : 526 - 533
  • [6] Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention
    Herrmann, HC
    Swierkosz, TA
    Kapoor, S
    Tardiff, DC
    DiBattiste, PM
    Hirshfeld, JW
    Klugherz, BD
    Kolansky, DM
    Magness, K
    Valettas, N
    Wilensky, RL
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (11) : 1293 - +
  • [7] Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions
    Kabbani, SS
    Aggarwal, A
    Terrien, EF
    DiBattiste, PM
    Sobel, BE
    Schneider, DJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (05) : 647 - +
  • [8] Frequency of major adverse cardiac events within one month of coronary angioplasty: A useful measure of operator performance
    Lindsay, J
    Pinnow, EE
    Pichard, AD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (07) : 1916 - 1923
  • [9] Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes
    Michalis, LK
    Tambaki, AP
    Katsouras, CS
    Goudevenos, JA
    Kolettis, T
    Adamides, K
    Tselepis, AD
    Sideris, DA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (02) : 108 - 112
  • [10] Osende JI, 2001, CIRCULATION, V103, P1488